Key Developments: Arch Therapeutics Inc (ARTH.OB)

ARTH.OB on OTC BB

0.19USD
17 Dec 2014
Price Change (% chg)

$-0.00 (-2.63%)
Prev Close
$0.19
Open
$0.20
Day's High
$0.20
Day's Low
$0.19
Volume
29,350
Avg. Vol
130,948
52-wk High
$0.45
52-wk Low
$0.15

Search Stocks

Latest Key Developments (Source: Significant Developments)

Arch Therapeutics reports positive preclinical data from study of AC5 Surgical Hemostatic Device in animals treated with Brilinta
Tuesday, 18 Nov 2014 08:57am EST 

Arch Therapeutics Inc:Says an independent third party has obtained positive data from a preclinical study assessing the use of AC5 in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta.Results of the study are consistent with separate data obtained from two recently completed preclinical studies.  Full Article

Arch Therapeutics Inc reports positive preclinical data from study of AC5 Surgical Hemostatic Device
Thursday, 6 Nov 2014 08:57am EST 

Arch Therapeutics Inc:Announces that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5 in animals that had been treated with therapeutic doses of the antiplatelet medications Plavix and aspirin alone and in combination.The results of the study are consistent with recent data obtained from two previous preclinical studies, in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin.  Full Article

Arch Therapeutics Inc negotiating collaboration agreement with CURAM Centre for Research in Medical Devices
Thursday, 23 Oct 2014 08:16am EDT 

Arch Therapeutics Inc:Says negotiating potential collaboration agreement with CÚRAM Centre for Research in Medical Devices.CÚRAM is major new national research center being established at the National University of Ireland Galway (NUIG) in Galway, Ireland, as part of six-year grant from the Irish government, which was announced earlier.Proceeds, which are expected to be released by Irish government in Jan. 2015, are intended to fund collaborative work performed by CÚRAM and its planned industry partners which, subject to execution of definitive collaboration agreement, would include Arch.  Full Article

Arch Therapeutics announces positive preclinical data from an independent study of AC5 Surgical Hemostatic Device(TM) in animals on blood thinners
Monday, 8 Sep 2014 07:57am EDT 

Arch Therapeutics Inc:Obtains positive data from a preclinical study assessing the use of AC5™ in animals receiving an anticoagulant medication.Results were consistent with the results obtained from a recently completed Arch study that showed that AC5 quickly stopped bleeding from surgical wounds created in the livers of rats that had been treated with a clinically relevant dose of the drug heparin.  Full Article

Arch Therapeutics announces positive preclinical data from its study of AC5 Surgical Hemostatic Device in Animals on Blood Thinner
Monday, 25 Aug 2014 07:58am EDT 

Arch Therapeutics Inc:Says positive data in an initial preclinical study assessing the use of its AC5 Surgical Hemostatic Device in animals receiving an anticoagulant medication (i.e. blood thinner).Heparin is an anticoagulant commonly given to patients to prevent blood clots during and after surgical procedures and in other circumstances.Study demonstrated that application of AC5 in this commonly used animal model of brisk bleeding was able to stop blood loss from the liver in less than 30 seconds and to achieve hemostasis.  Full Article

Arch Therapeutics Inc announces collaboration with University College Cork School of Pharmacy
Tuesday, 22 Jul 2014 08:30am EDT 

Arch Therapeutics Inc:Entered into new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products.Arch is a medical device company developing approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. AC5 is product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care.Arch has developed a network of European and American collaborators in academic institutions and industry.As an example of Arch's cooperative development model, this collaboration extends a successful multi-year relationship between Arch and institutions within NUI.A prior Arch collaboration with UCC, University College Dublin, and the Royal College of Surgeons in Ireland received support from the prestigious Science Foundation Ireland.In current and prior partnerships, Arch leadership, technology and resources have combined with Irish academic institutional scientists and assets in order to drive product development.  Full Article

Arch Therapeutics Inc appoints Richard Davis as Chief Financial Officer
Monday, 7 Jul 2014 06:07pm EDT 

Arch Therapeutics Inc:Appoints Richard Davis as Chief Financial Officer and Treasurer.Company's current Chief Financial Officer and Treasurer, Alan Barber, has resigned from his position effective July 07, 2014 and has become an advisor to company.  Full Article

Arch Therapeutics Inc secures $2.85 mln private placement
Monday, 10 Feb 2014 09:00am EST 

Arch Therapeutics Inc:Closes a previously announced private placement to accredited individual and institutional investors.Says transaction provided about $2.77 mln of net proceeds to the company, after expenses.Intends to use the offering proceeds to advance its hemostasis development program, predominantly focusing on AC5 Surgical Hemostatic Device, and for general corporate purposes.Says it did not engage a placement agent in connection with the private placement.  Full Article

Arch Therapeutics Inc announces $2.85 mln private placement
Friday, 31 Jan 2014 06:00am EST 

Arch Therapeutics Inc:Says its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share pursuant to the terms of a securities purchase agreement dated Jan. 30, 2014.Says the private placement is expected to close on or about Feb. 4.Says the gross proceeds of the offering are expected to be about $2.85 mln.Says the net proceeds, after deducting estimated offering expenses payable by Arch, are expected to be about $2.77 mln.Says it not engage a placement agent in connection with the private placement.Says it intends to use the offering proceeds to advance its hemostasis development program, predominantly focusing on AC5 Surgical Hemostatic Device, and for general corporate purposes.  Full Article

Arch Therapeutics Inc Enters Into Sciences Accelerator Funding Agreement With Massachusetts Life Sciences Center-Form 8-K
Friday, 4 Oct 2013 02:03pm EDT 

Arch Therapeutics Inc reported in its Form 8-K that on September 30, 2013, the Company entered into the Life Sciences Accelerator Funding Agreement (the MLSC Loan Agreement) with the Massachusetts Life Sciences Center (MLSC), pursuant to which MLSC has agreed to provide the Company an unsecured subordinated loan, and the Company has issued to MLSC a related promissory note, in principal amount of $1,000,000 (such loan, the MLSC Loan). The Company expects to receive the full amount of the MLSC Loan on or about October 8, 2013. The MLSC Loan will bear interest at a rate of 10% per annum, and will become fully due and payable on the earlier of September 30, 2018, the occurrence of an event of default under the MLSC Loan Agreement, or the completion of a sale of substantially all of the Company’s assets, a change-of-control transaction or one or more financing transactions in which the Company receives net proceeds of $5,000,000 or more in a 12-month period. Pursuant to the terms of the MLSC Loan Agreement, the Company may use the proceeds of the MLSC Loan solely to fund working capital requirements and/or the purchase of capital assets in the life sciences field, and the Company is expressly prohibited from using any such proceeds for any severance payment, investment in certain securities or payment of goods or services to a related party of the Company.  Full Article

No consensus analysis data available.
Search Stocks